Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
Leukemias|Myelodysplastic Syndromes
DRUG: sapacitabine
Maximum tolerated dose, dose limiting toxicities; during first cycle, each cycle is three weeks, Through study completion, average of 1 year
The goal of this study is to find the highest tolerable dose of sapacitabine that can be given to patients with advanced leukemias or myelodysplastic syndromes.